Sapience Investments LLC Increases Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Sapience Investments LLC boosted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 17.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,775 shares of the life sciences company's stock after purchasing an additional 24,830 shares during the period. Integra LifeSciences comprises approximately 2.2% of Sapience Investments LLC's holdings, making the stock its 6th largest position. Sapience Investments LLC owned about 0.21% of Integra LifeSciences worth $3,737,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in IART. Quadrant Capital Group LLC increased its position in Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares during the period. Covestor Ltd boosted its position in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after acquiring an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in Integra LifeSciences during the fourth quarter worth approximately $180,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Wall Street Analyst Weigh In

IART has been the subject of several analyst reports. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Wells Fargo & Company reduced their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial decreased their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. JPMorgan Chase & Co. cut their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities lowered their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Trading Down 4.7%

IART stock traded down $0.63 during mid-day trading on Wednesday, reaching $12.69. 1,348,305 shares of the stock traded hands, compared to its average volume of 1,048,936. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66. The stock's fifty day moving average is $17.64 and its 200-day moving average is $21.60. The company has a market cap of $986.17 million, a P/E ratio of -140.98, a P/E/G ratio of 0.73 and a beta of 1.27. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm's quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 earnings per share. As a group, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.